Clinical Efficacy and Safety Study of Octreotide Combined with Thrombin in Liver Cirrhosis Combined with Upper Gastrointestinal Bleeding

Zhu Haibo; Yang Weixuan; Liu Cheng

doi:10.3969/j.issn.1004-5775.2025.09.010

Abstract：Objective:To analyze the effect of octreotide combined with thrombin in liver cirrhosis combined with upper gastrointestinal bleeding.Methods:78 patients with cirrhosis and upper gastrointestinal bleeding from March 2022 to March 2024 were selected,and they were divided into control group and strudy group,with 39 cases in each group.Both groups were treated routinely.The control group combined with thrombin,and the study received octreotide.Clinical efficacy,hemostasis,liver function,adverse effects and quality of life were compared between the two groups.Results:The clinical effect of the study group was better than that of the control group,and the difference was statistically significant(χ2=3.923,P<0.05).The hemostasis time of the study group was shorter than that of the control group,and the blood transfusion volume was lower,with statistically significant difference(t=9.546,25.185;P<0.05).After treatment,ALT,AST and TBiL levels in the study group were lower than those in the control group,with statistically significant difference(t=13.336,12.571,17.796;P<0.05).The incidence of adverse reactions in the study group was significantly lower than that the control group(χ2=5.014,P<0.05).After treatment,the WHOQOL-100 score of the study group was higher than that of the control group,with statistically significant difference(t=4.078,2.722,5.018,3.675,2.088;P<0.05).Conclusion:Octreotide combined with thrombin in cirrhosis combined with upper gastrointestinal bleeding has high clinical efficacy.It can shorten the hemostasis time,promote the liver function,and improve the quality of life.And it is high safety.